TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB Share Price
Certificat
DE000SW88X00
| Market Closed - Deutsche Boerse AG 01:09:54 01/06/2024 am IST | ||
| 10.67 EUR | -1.48% |
|
| 1 month | +0.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 10.67 | -1.48% |
| 30/24/30 | 10.83 | -1.46% |
| 29/24/29 | 10.99 | +1.48% |
| 28/24/28 | 10.83 | +1.69% |
| 27/24/27 | 10.65 | -3.71% |
Delayed Quote Deutsche Boerse AG
Last update May 01, 2024 at 01:09 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW88X0 |
| ISIN | DE000SW88X00 |
| Date issued | 19/04/2024 |
| Strike | 2,732 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.28 € |
|---|---|
| Lowest since issue | 9.06 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,937
DKK
Average target price
2,466
DKK
Spread / Average Target
+27.30%
- Stock Market
- Certificates
- Certificat
